Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib with mFOLFIRINOX in Advanced Pancreatic Cancer
NCT04228601Phase 2Completed
- Sponsor
- Hengrui
- Start
- Jan 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Fluzoparib+mFOLFIRINOX with Placebo+mFOLFIRINOX (2 arms). Primary endpoints: Number of Participants With a Dose Limited Toxicity at 28 days, Maximum Tolerated Dose at 8 months and 2 more. Started Jan 2020; status: completed.
02
Drugs
fluzoparib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04228601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228601.